260 related articles for article (PubMed ID: 34120766)
1. Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.
Dal-Ré R; Launay O
Vaccine; 2021 Jul; 39(30):4029-4031. PubMed ID: 34120766
[No Abstract] [Full Text] [Related]
2. Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.
Parums DV
Med Sci Monit; 2022 Mar; 28():e936523. PubMed ID: 35228506
[TBL] [Abstract][Full Text] [Related]
3. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
Sønderskov KM; Dinesen PT; Østergaard SD
Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
[TBL] [Abstract][Full Text] [Related]
4. The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans.
Dal-Ré R
Therapie; 2023; 78(3):293-302. PubMed ID: 35907680
[TBL] [Abstract][Full Text] [Related]
5. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
6. When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine.
Dal-Ré R; Banzi R
Eur J Intern Med; 2021 May; 87():1-2. PubMed ID: 33810939
[No Abstract] [Full Text] [Related]
7. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.
Tumban E
Viruses; 2020 Dec; 13(1):. PubMed ID: 33396343
[TBL] [Abstract][Full Text] [Related]
8. Don't shortchange public trust in science.
Nat Cancer; 2020; 1(9):855-856. PubMed ID: 32935085
[TBL] [Abstract][Full Text] [Related]
9. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.
Neurosciences (Riyadh); 2021 Apr; 26(2):222-223. PubMed ID: 33814381
[No Abstract] [Full Text] [Related]
10. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
[TBL] [Abstract][Full Text] [Related]
11. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.
Saudi Med J; 2021 Mar; 42(3):344-345. PubMed ID: 33632917
[No Abstract] [Full Text] [Related]
12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
13. Did the European suspension of the AstraZeneca vaccine decrease vaccine acceptance during the COVID-19 pandemic?
Petersen MB; Jørgensen F; Lindholt MF
Vaccine; 2022 Jan; 40(4):558-561. PubMed ID: 34952752
[TBL] [Abstract][Full Text] [Related]
14. Adverse Consequences of Rushing a SARS-CoV-2 Vaccine: Implications for Public Trust.
Trogen B; Oshinsky D; Caplan A
JAMA; 2020 Jun; 323(24):2460-2461. PubMed ID: 32453392
[No Abstract] [Full Text] [Related]
15. Vaccine safety - is the SARS-CoV-2 vaccine any different?
Tau N; Yahav D; Shepshelovich D
Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
[TBL] [Abstract][Full Text] [Related]
16. Orofacial adverse effects of COVID-19 vaccines exist but are rare.
Sofi-Mahmudi A
Evid Based Dent; 2021 Jan; 22(2):70-71. PubMed ID: 34172912
[TBL] [Abstract][Full Text] [Related]
17. Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
Nguyen S; Bastien E; Chretien B; Sassier M; Defer G; Nehme A; Lelong-Boulouard V; Alexandre J; Fedrizzi S; Morice PM
Ann Neurol; 2022 Dec; 92(6):1080-1089. PubMed ID: 36054163
[TBL] [Abstract][Full Text] [Related]
18. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
Lamb YN
Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637
[TBL] [Abstract][Full Text] [Related]
19. Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines.
Mahallawi WH; Mumena WA
Front Immunol; 2021; 12():794642. PubMed ID: 34925378
[TBL] [Abstract][Full Text] [Related]
20. Building public trust in COVID-19 vaccines through the Catholic Church in the Philippines.
Gopez JMW
J Public Health (Oxf); 2021 Jun; 43(2):e330-e331. PubMed ID: 33640960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
